On Tuesday, Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was -6.35% drop from the session before settling in for the closing price of $1.89. A 52-week range for VRCA has been $1.85 – $11.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -13.60% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -1.80%. With a float of $26.07 million, this company’s outstanding shares have now reached $42.41 million.
In an organization with 100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.14%, operating margin of -563.14%, and the pretax margin is -625.06%.
Verrica Pharmaceuticals Inc (VRCA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verrica Pharmaceuticals Inc stocks. The insider ownership of Verrica Pharmaceuticals Inc is 38.89%, while institutional ownership is 43.77%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.80% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
You can see what Verrica Pharmaceuticals Inc (VRCA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.44 million. That was better than the volume of 0.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.73%. Additionally, its Average True Range was 0.30.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.75% in the past 14 days, which was lower than the 111.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.6880, while its 200-day Moving Average is $5.9973. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $1.8933. Second resistance stands at $2.0167. The third major resistance level sits at $2.0783. If the price goes on to break the first support level at $1.7083, it is likely to go to the next support level at $1.6467. Assuming the price breaks the second support level, the third support level stands at $1.5233.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
There are 42,420K outstanding shares of the company, which has a market capitalization of 75.53 million. As of now, sales total 5,120 K while income totals -67,000 K. Its latest quarter income was 5,180 K while its last quarter net income were -17,190 K.
